Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September)
Links shared publicly online about this topic.
- 83total visits
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September)
View full resource at theannals.com
Tags: Liver Condition, Hepatitis, Hepatitis C, Boceprevir
Most Recently Shared on August 10, 2011 at 4:57 am By:
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September): OBJECTIVE:To review the p... http://bit.ly/rrZDSP
HCV New Drug Research: Hepatitis News; Weekend Update
hepatitiscnewdrugs.blogspot.com — “HCV New Drug Research: Hepatitis News; Weekend Update” View full resource at hepatitiscnewdrugs.blogspot.com
Most Recently Shared on August 14, 2011 at 4:09 pm By:
Tina Banwart - HepatitisCNewDrugs Health Blog
FRONTLINE The Pot Republic http://t.co/ZdM6pbs
Late-breaking news: FDA approves boceprevir for hepatitis C - - ModernMedicine
modernmedicine.com — “FDA has approved boceprevir (Victrelis, Merck) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients aged 18 years and older with compensated liver disease.” View full resource at modernmedicine.com
Most Recently Shared on May 19, 2011 at 5:35 pm By:
Raymond DuBois Physician, Doctor, Internist, Gastroenterologist, and Health Executive
FDA Approves Protease Inhibitor To Treat Chronic Hepatitis C http://tinyurl.com/3peohf4
Victrelis Approved for Chronic Hepatitis C - MPR
empr.com — “Merck announced that the FDA has approved Victrelis (boceprevir), a hepatitis C virus protease inhibitor, for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients 18 years of age with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.” View full resource at empr.com
Most Recently Shared on May 16, 2011 at 3:31 pm By:
MPR News: Victrelis Approved for Chronic Hepatitis C: Merck announced that the FDA has approved Victrelis (bocep... http://bit.ly/j1wL3a
Victrelis Approved for Chronic Hepatitis C - ONA
oncologynurseadvisor.com — “Merck announced that the FDA has approved Victrelis (boceprevir), a hepatitis C virus protease inhibitor, for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients 18 years of age with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 16, 2011 at 3:14 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Victrelis Approved for Chronic Hepatitis C http://goo.gl/fb/Sjo2D
New Treatment for Chronic Hepatitis C Infection? - QualityPoint Technologies
qualitypointtech.net — “The protease inhibitor boceprevir, added to conventional therapy, raised response rates in patients with hepatitis C genotype 1, but it's still awaiting FDA approval. Journal Watch” View full resource at qualitypointtech.net
Most Recently Shared on May 16, 2011 at 2:45 pm By:
New Treatment for Chronic Hepatitis C Infection?: The protease inhibitor boceprevir, added to conventional therapy... http://bit.ly/mrUwYR
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients With Chronic HCV Genotype 1
medicalnewstoday.com — “MSD reported that final results from a Phase III study of 'Victrelis'™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a ('Pegasys'®)” View full resource at medicalnewstoday.com
Most Recently Shared on April 1, 2011 at 11:05 pm By:
'Victrelis'™ Added To Peginterferon Alfa-2a And Ribavirin Gives Higher Cure Rates In Treatment-Failure Patients ... http://mnt.to/3T54
A Better Way to Unbind Prometheus? Boceprevir for the Treatment of Chronic Hepatitis C Infection | Now@NEJM
blogs.nejm.org — “(copyright 2006, Scott Eaton) What do Mickey Mantle, Evel Knievel, and Pamela Anderson have in common? Infamy, certainly, but all three are also” View full resource at blogs.nejm.org
Most Recently Shared on March 30, 2011 at 9:07 pm By:
NOW@NEJM post covers two new articles on boceprevir for Hep C. These HCV protease inhibitors a “significant step.†http://bit.ly/hivpbU
Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection
news-medical.net — “Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.” View full resource at news-medical.net
Most Recently Shared on November 1, 2010 at 7:51 am By:
Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection: Merck reported... http://bit.ly/bdNMKj
NHS Evidence - Gastroenterology and liver diseases - Horizon scanning: Phase III studies of oral hepatitis C treatment boceprevir meet primary endpoints
library.nhs.uk — “Two phase III studies of the protease inhibitor boceprevir in patients with chronic hepatitis C virus (HCV) genotype 1 infection have been completed and met their primary endpoints. The HCV RESPOND-2 and HCV SPRINT-2 studies each evaluated two treatment strategies with boceprevir: 48 weeks of treatment for all patients (4-week lead-in with 1.5mcg/kg/week of peginterferon alfa-2b [Peg] and an investigational dose of 600-1400mg/day of ribavirin (riba) followed by the addition of boceprevir 800mg t” View full resource at library.nhs.uk
Most Recently Shared on August 17, 2010 at 11:22 am By:
Horizon scanning: Phase III studies of oral hepatitis C treatment boceprevir meet primary endpoints: (Source: NHS ... http://bit.ly/9fIZiT
Advertisement
